Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C, Chronic

Explore clinical trials studying Hepatitis C, Chronic. Study availability and eligibility vary by location and protocol.

314 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C, Chronic trial results

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham, Alabama, United States
  • Little Rock, Arkansas, United States
  • Sacramento, California, United States
  • San Diego, California, United States
View all 41 locations
View Trial Details
Completed

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

NCT00107653

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Fountain Valley, California, United States
View all 60 locations
View Trial Details
Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

NCT00700401

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Vitória, Espírito Santo, Brazil
  • Brasília, Federal District, Brazil
  • São Luís, Maranhão, Brazil
  • Rio de Janeiro, Brazil
View Trial Details
Completed

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

NCT01525628

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.27.0006 Boehringer Ingelheim Investigational Site La Mesa, California, United States
  • 1241.27.0005 Boehringer Ingelheim Investigational Site Rockville, Maryland, United States
  • 1241.27.0004 Boehringer Ingelheim Investigational Site Marlton, New Jersey, United States
  • 1241.27.0003 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States
View all 16 locations
View Trial Details
Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Bakersfield, California, United States
  • Pasadena, California, United States
  • San Diego, California, United States
  • San Mateo, California, United States
View all 25 locations
View Trial Details
Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

NCT00905632

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.7.3307A CHU de Grenoble Grenoble Cédex 9, France
  • 1241.7.3303A Hôpital Claude Huriez Lille, France
  • 1241.7.3302A Hopital de l'Hotel Dieu Lyon, France
  • 1241.7.3301A Hôpital Saint Eloi Montpellier, France
View all 18 locations
View Trial Details
Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

NCT01732796

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.20.00026 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 1241.20.00033 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
  • 1241.20.00006 Boehringer Ingelheim Investigational Site La Mesa, California, United States
  • 1241.20.00003 Boehringer Ingelheim Investigational Site Oceanside, California, United States
View all 101 locations
View Trial Details

Related conditions